Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
REVENUES:
Revenue	$ 115,300	$ 108,383
OPERATING EXPENSES:
General and administrative expense, exclusive of depreciation expense shown below	12,545	8,461
Depreciation	4,384	4,633
Amortization	173	238
Other (income) expense, net	1,637	(721)
OPERATING INCOME (LOSS)	(391)	11,622
Interest expense	2,644	1,363
Income (loss) from continuing operations before income taxes	(3,035)	10,259
Income tax expense (benefit)	(1,196)	2,052
Income (loss) from continuing operations	(1,839)	8,207
Net income (loss)	(1,839)	8,207
Net income (loss) attributable to non-controlling interest	49	102
Net income (loss) attributable to Core Laboratories N.V.	$ (1,888)	$ 8,105
EARNINGS (LOSS) PER SHARE INFORMATION:
Basic earnings (loss) per share from continuing operations	$ (0.04)	$ 0.18
Basic earnings (loss) per share attributable to Core Laboratories N.V.	(0.04)	0.18
Diluted earnings (loss) per share from continuing operations	(0.04)	0.18
Diluted earnings (loss) per share attributable to Core Laboratories N.V.	$ (0.04)	$ 0.18
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in shares)	46,298	45,177
Assuming Dilution (in shares)	46,298	45,964
Service [Member]
REVENUES:
Revenue	$ 84,723	$ 83,982
OPERATING EXPENSES:
Cost of services and product sales exclusive of depreciation expense and inventory write-down shown below	68,857	63,533
Product [Member]
REVENUES:
Revenue	30,577	24,401
OPERATING EXPENSES:
Cost of services and product sales exclusive of depreciation expense and inventory write-down shown below	$ 28,095	$ 20,617